Australian regulator TGA warns of ‘rare but severe’ eye disorder linked to GLP-1 drugs like Ozempic
The Therapeutic Goods Administration warning came after several GLP-1 RA medicines, marketed in Australia as Ozempic, Wegovy and Mounjaro among other products, were linked to 36 cases of the eye disorder, non-arteritic anterior ischaemic optic neuropathy. Photograph: James Manning/PAView image in fullscreenThe Therapeutic Goods Administration warning came after several GLP-1 RA medicines, marketed in Australia as Ozempic, Wegovy and Mounjaro among other products, were linked to 36 cases of the eye disorder, non-arteritic anterior ischaemic optic neuropathy. It’s one of the greatest concerns that people have,” she said.“But it’s still a very rare condition, while the other conditions these medications treat are very common, like heart attacks, stroke and kidney disease.
- ▪The Therapeutic Goods Administration warning came after several GLP-1 RA medicines, marketed in Australia as Ozempic, Wegovy and Mounjaro among other products, were linked to 36 cases of the eye disorder, non-arteritic anterior ischaemic op
- ▪Photograph: James Manning/PAView image in fullscreenThe Therapeutic Goods Administration warning came after several GLP-1 RA medicines, marketed in Australia as Ozempic, Wegovy and Mounjaro among other products, were linked to 36 cases of t
- ▪It’s one of the greatest concerns that people have,” she said.“But it’s still a very rare condition, while the other conditions these medications treat are very common, like heart attacks, stroke and kidney disease.
The Guardian — World publishes from United Kingdom and files mainly under world. We currently carry 2,580 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | The Guardian — World |
| Canonical URL | https://www.theguardian.com/australia-news/2026/jul/24/tga-warning-gpl1-eye-disorder-drugs-ozempic-wegovy-mounjaro |
| Publication time | Fri, 24 Jul 2026 06:39:09 GMT |
| Retrieval time | 2026-07-24T06:50:55.931Z |
| Last seen | 2026-07-24T06:50:55.931Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | P3DP6aEqwzXV |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
The Therapeutic Goods Administration warning came after several GLP-1 RA medicines, marketed in Australia as Ozempic, Wegovy and Mounjaro among other products, were linked to 36 cases of the eye disorder, non-arteritic anterior ischaemic optic neuropathy. Photograph: James Manning/PAView image in fullscreenThe Therapeutic Goods Administration warning came after several GLP-1 RA medicines, marketed in Australia as Ozempic, Wegovy and Mounjaro among other products, were linked to 36 cases of the eye disorder, non-arteritic anterior ischaemic optic neuropathy.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at The Guardian — World.
Discussion
0 commentsMore from The Guardian — World
